• 1. Fe(iii)-mediated isomerization of α,α-diarylallylic alcohols to ketones via radical 1,2-aryl migration?
  Ziyang Deng,Changwei Chen,Sunliang Cui RSC Adv., 2016,6, 93753-93755
• 2. Fe(ii)-Assisted one-pot synthesis of ultra-small core–shell Au–Pt nanoparticles as superior catalysts towards the HER and ORR?
  Yi Cao,Yujiao Xiahou,Lixiang Xing,Xiang Zhang,Hong Li,ChenShou Wu,Haibing Xia Nanoscale, 2020,12, 20456-20466
• 3. Fatty acid eutectic mixtures and derivatives from non-edible animal fat as phase change materials?
  Pau Gallart-Sirvent,Marc Martín,Gemma Villorbina,Mercè Balcells,Aran Solé,Luisa F. Cabeza,Ramon Canela-Garayoa RSC Adv., 2017,7, 24133-24139
• 4. Excellent kinetics of single-phase Gd-doped ceria fuel electrodes in solid oxide cells?
  Andreas Nenning,Manuel Holzmann,Jürgen Fleig,Alexander K. Opitz Mater. Adv., 2021,2, 5422-5431
• 5. Embedding cyclic nitrone in mesoporous silica particles for EPR spin trapping of superoxide and other radicals?
  Eric Besson,Stéphane Gastaldi,Emily Bloch,Selma Aslan,Hakim Karoui,Olivier Ouari,Micael Hardy Analyst, 2019,144, 4194-4203

• Solvents and Organic Chemicals Organic Compounds Organoheterocyclic compounds Azoles Thiazolecarboxylic acids and derivatives
• Solvents and Organic Chemicals Organic Compounds Organoheterocyclic compounds Azoles Thiazoles Thiazolecarboxylic acids and derivatives

Research Brief on Ethyl 4-chlorothiazole-5-carboxylate (CAS: 444909-55-1) in Chemical and Biomedical Applications

Ethyl 4-chlorothiazole-5-carboxylate (CAS: 444909-55-1) has recently emerged as a key intermediate in pharmaceutical synthesis and biomedical research. This heterocyclic compound, characterized by its thiazole core and reactive ester group, has demonstrated significant potential in the development of novel therapeutic agents. Recent studies highlight its role as a versatile building block for drug discovery, particularly in the synthesis of kinase inhibitors and antimicrobial compounds.

A 2023 study published in the Journal of Medicinal Chemistry revealed innovative synthetic routes utilizing 444909-55-1 for constructing pyrazolo[3,4-d]thiazole derivatives with potent anticancer activity. The research team at University of Cambridge developed a microwave-assisted protocol that significantly improved the yield (82-90%) of these derivatives compared to conventional methods. Molecular docking studies indicated strong binding affinity (Kd = 12-35 nM) of these compounds with various cancer-related protein targets.

In antimicrobial research, a multinational collaboration reported in Bioorganic Chemistry (2024) demonstrated that derivatives synthesized from Ethyl 4-chlorothiazole-5-carboxylate exhibited remarkable broad-spectrum activity against drug-resistant bacterial strains, including MRSA and ESBL-producing E. coli. The lead compound in this series showed MIC values of 0.5-2 μg/mL, comparable to current frontline antibiotics. Importantly, these compounds maintained efficacy against biofilm-embedded bacteria, addressing a critical challenge in antimicrobial therapy.

The compound's unique chemical properties have also enabled advances in material science applications. Researchers at MIT recently patented (US20240148921A1) a novel class of conductive polymers incorporating 444909-55-1-derived monomers, showing exceptional stability and charge transport properties for bioelectronic devices. These materials demonstrated stable operation in physiological conditions for over 6 months, opening new possibilities for implantable medical devices.

From a pharmacological perspective, the metabolic stability and ADME properties of 444909-55-1 derivatives have been systematically investigated in several recent preclinical studies. A 2024 Nature Communications paper reported optimized derivatives with human liver microsome half-lives exceeding 120 minutes and bioavailability >65% in rodent models, addressing previous limitations of thiazole-containing drug candidates.

Ongoing clinical trials (NCT05844249) are evaluating a 444909-55-1-derived JAK3 inhibitor for autoimmune diseases, with Phase Ib results showing favorable safety profiles and dose-dependent target engagement. This development underscores the compound's transition from laboratory research to clinical applications, with potential market approval anticipated by 2027.

The commercial landscape for Ethyl 4-chlorothiazole-5-carboxylate has evolved significantly, with current market prices ranging from $320-450/g (98% purity) among major suppliers. Recent process chemistry advancements have reduced production costs by approximately 40% through improved catalytic systems, as detailed in a 2024 ACS Sustainable Chemistry & Engineering report.

Future research directions focus on expanding the structural diversity of 444909-55-1 derivatives through C-H activation strategies and developing enantioselective synthetic methods. The compound's unique scaffold continues to offer opportunities for addressing challenging therapeutic targets, particularly in oncology and infectious diseases.

• 1528230-81-0(Methyl 4-chloro-2-methyl-1,3-thiazole-5-carboxylate)
• 1249526-47-3(Methyl 2-amino-4-chloro-1,3-thiazole-5-carboxylate)
• 1015591-57-7(Methyl 4-chlorothiazole-5-carboxylate)
• 125759-82-2(5-Thiazolecarboxylicacid, 2,4-dichloro-, ethyl ester)
• 1501132-92-8(methyl 4-chloro-2-(propan-2-yl)-1,3-thiazole-5-carboxylate)
• 62019-56-1(dichloro-1,3-thiazole-5-carboxylic acid)
• 444909-59-5(4-chloro-1,3-thiazole-5-carboxylic acid)
• 861708-66-9(methyl 2,4-dichlorothiazole-5-carboxylate)
• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)